Solvonis reports positive bridging data for SVN-002 ahead of planned US Phase 2b
uniQure reports initial six‑month data from first AMT‑260 dose cohort
Incyte Japan wins approval for Minjuvi combination therapy in relapsed or refractory DLBCL
Teijin and Merz secure Japanese approval for additional XEOMIN indications
Alvotech raises USD165m in public offering and private placement
Oncoinvent reports recruitment milestone in Phase 2 study of Radspherin in ovarian cancer
Nortiva Bio launches to develop long-acting oral medicines using LYNX platform
FDA accepts Genentech application for Lunsumio and Polivy combination in large B-cell lymphoma
Ananda Pharma reports Phase 1 pharmacokinetic study results for MRX1
NMD Pharma reports further data from Phase 2a study of ignaseclant
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
Bayer completes acquisition of Perfuse Therapeutics to strengthen ophthalmology pipeline
Akeso reports Phase II data for ligufalimab in AML
Optimi Health introduces standardised microdose psilocybin capsules for clinical research